Ziresovir

Summary

Ziresovir (CHEMBL4468815) is a phase-3 clinical-stage small molecule; indicated across 1 condition including respiratory syncytial virus infectious disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 11
• Chemistry: 439.5 Da · C22H25N5O3S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4468815
Name	Ziresovir
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	71262247
Molecular formula	C22H25N5O3S
Molecular weight	439.5
InChIKey	GAAICKUTDBZCMT-UHFFFAOYSA-N

SMILES: CC1=CC2=C(C=C1)N=C(N=C2NCC3(COC3)N)N4CCS(=O)(=O)C5=CC=CC=C5C4

IUPAC name: N-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-2H-1lambda6,4-benzothiazepin-4-yl)-6-methylquinazolin-4-amine

Also known as: AK-0529, Ak0529, AK0529, RO-0529, Ziresovir, ZIRESOVIR

Patent coverage: 71 distinct patent families (208 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 181 (87%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Fusion glycoprotein F0.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P03420	5.68	EC50	2100	nM	CHEMBL_ACT_19088202

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
respiratory syncytial virus infectious disease	3	MONDO:0001577	EFO:1001413

Clinical trials

Total trials: 11.

Phase distribution

Phase	Trials
PHASE1	6
PHASE2	3
PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06775405	PHASE3	RECRUITING	A Study to Confirm the Effectiveness and Safety of AK0529 in Treating RSV Infections in Hospitalized Infants
NCT04231968	PHASE3	COMPLETED	A Study of AK0529 in Chinese Infants Hospitalized With RSV
NCT02654171	PHASE2	COMPLETED	Viral Inhibition in Children for Treatment of RSV
NCT03699202	PHASE2	UNKNOWN	Anti-RSV Study in Chinese Patients (ASCENT)
NCT06942299	PHASE2	COMPLETED	A Study of AK0529 in Adults Patients Hospitalized With RSV Infection
NCT06591845	PHASE1	NOT_YET_RECRUITING	Thorough QT/QTc (TQT) Clinical Study to Evaluate the Effects of Ziresovir on Cardiac Repolarization in Healthy Subjects
NCT02297594	PHASE1	COMPLETED	Safety, Tolerability and PK Study of AK0529 in Healthy Human
NCT02460016	PHASE1	TERMINATED	A Study of AK0529 in Infants Hospitalized With RSV
NCT03322800	PHASE1	COMPLETED	A Study of AK0529 to Evaluate Pharmacokinetics and Safety in Chinese Healthy Volunteers
NCT03400995	PHASE1	COMPLETED	A Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of AK0529
NCT04788017	PHASE1	COMPLETED	A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ziresovir in Healthy Subjects

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).